Cargando…

Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia

BACKGROUND: Extended spectrum Beta-lactamases (ESBLs) and AmpC beta-lactamases (AmpC) are the common enzymes produced by gram negative bacilli, which are their main mechanisms of resistance to all generations of cephalosporins. Hence, this study aimed to determine the magnitude of ESBLs and AmpC pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tekele, Saba Gebremichael, Teklu, Dejenie Shiferaw, Tullu, Kassu Desta, Birru, Samuel Kinde, Legese, Melese Hailu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660541/
https://www.ncbi.nlm.nih.gov/pubmed/33180785
http://dx.doi.org/10.1371/journal.pone.0241984
_version_ 1783609026102165504
author Tekele, Saba Gebremichael
Teklu, Dejenie Shiferaw
Tullu, Kassu Desta
Birru, Samuel Kinde
Legese, Melese Hailu
author_facet Tekele, Saba Gebremichael
Teklu, Dejenie Shiferaw
Tullu, Kassu Desta
Birru, Samuel Kinde
Legese, Melese Hailu
author_sort Tekele, Saba Gebremichael
collection PubMed
description BACKGROUND: Extended spectrum Beta-lactamases (ESBLs) and AmpC beta-lactamases (AmpC) are the common enzymes produced by gram negative bacilli, which are their main mechanisms of resistance to all generations of cephalosporins. Hence, this study aimed to determine the magnitude of ESBLs and AmpC producing gram negative bacilli (GNB) isolated from clinical specimens at International clinical Laboratories in Addis Ababa, Ethiopia. METHODS: A cross sectional study was conducted from January to May 2018. From different clinical specimens, 338 GNB were isolated and characterized. Bacterial species identification, antimicrobial susceptibility testing and screening for ESBLs and AmpC production were performed using Phoenix automated system (BD phoenix(100)). ESBLs production was confirmed using a combination disc method. All Cefoxitin resistant and confirmed ESBLs producing GNB were confirmed for AmpC beta-lactamases production by AmpC confirmatory Neo-Sensitabs discs (ROSCO tablet). Data were analyzed using SPSS version 20 software. RESULTS: E. coli 66.0% (224/338) followed by K. pneumoniae 12.1% (41/338) were GNB most frequently isolated. The overall magnitude of ESBLs producing GNB was 38.8% (131/338) and the extent of AmpC beta-lactamase producing GNB was 2.4% (8/338). Majority of ESBLs and AmpC beta-lactamases producing GNB were isolated from urine specimens 47.5% (116/338). Ampicillin (75.4%), amoxicillin with clavulanic acid (64.0%) and sulfamethoxazole-trimethoprim (55.6%) were most the antibiotics to which resistance was most commonly found. The multidrug resistance (MDR) level of GNB was 74.0% (250/338). Of ESBLs and AmpC beta-lactamases producing GNB, 99.3% were MDR (p < 0.05). CONCLUSION: The high magnitude of ESBLs and AmpC beta-lactamases producing GNB calls the needs of strong intervention to minimize further occurrence and spread of such GNB. More importantly, the MDR level was high which suggests continuous monitoring & reviewing of antimicrobial policy in hospitals and the country at large.
format Online
Article
Text
id pubmed-7660541
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76605412020-11-18 Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia Tekele, Saba Gebremichael Teklu, Dejenie Shiferaw Tullu, Kassu Desta Birru, Samuel Kinde Legese, Melese Hailu PLoS One Research Article BACKGROUND: Extended spectrum Beta-lactamases (ESBLs) and AmpC beta-lactamases (AmpC) are the common enzymes produced by gram negative bacilli, which are their main mechanisms of resistance to all generations of cephalosporins. Hence, this study aimed to determine the magnitude of ESBLs and AmpC producing gram negative bacilli (GNB) isolated from clinical specimens at International clinical Laboratories in Addis Ababa, Ethiopia. METHODS: A cross sectional study was conducted from January to May 2018. From different clinical specimens, 338 GNB were isolated and characterized. Bacterial species identification, antimicrobial susceptibility testing and screening for ESBLs and AmpC production were performed using Phoenix automated system (BD phoenix(100)). ESBLs production was confirmed using a combination disc method. All Cefoxitin resistant and confirmed ESBLs producing GNB were confirmed for AmpC beta-lactamases production by AmpC confirmatory Neo-Sensitabs discs (ROSCO tablet). Data were analyzed using SPSS version 20 software. RESULTS: E. coli 66.0% (224/338) followed by K. pneumoniae 12.1% (41/338) were GNB most frequently isolated. The overall magnitude of ESBLs producing GNB was 38.8% (131/338) and the extent of AmpC beta-lactamase producing GNB was 2.4% (8/338). Majority of ESBLs and AmpC beta-lactamases producing GNB were isolated from urine specimens 47.5% (116/338). Ampicillin (75.4%), amoxicillin with clavulanic acid (64.0%) and sulfamethoxazole-trimethoprim (55.6%) were most the antibiotics to which resistance was most commonly found. The multidrug resistance (MDR) level of GNB was 74.0% (250/338). Of ESBLs and AmpC beta-lactamases producing GNB, 99.3% were MDR (p < 0.05). CONCLUSION: The high magnitude of ESBLs and AmpC beta-lactamases producing GNB calls the needs of strong intervention to minimize further occurrence and spread of such GNB. More importantly, the MDR level was high which suggests continuous monitoring & reviewing of antimicrobial policy in hospitals and the country at large. Public Library of Science 2020-11-12 /pmc/articles/PMC7660541/ /pubmed/33180785 http://dx.doi.org/10.1371/journal.pone.0241984 Text en © 2020 Tekele et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tekele, Saba Gebremichael
Teklu, Dejenie Shiferaw
Tullu, Kassu Desta
Birru, Samuel Kinde
Legese, Melese Hailu
Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia
title Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia
title_full Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia
title_fullStr Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia
title_full_unstemmed Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia
title_short Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia
title_sort extended-spectrum beta-lactamase and ampc beta-lactamases producing gram negative bacilli isolated from clinical specimens at international clinical laboratories, addis ababa, ethiopia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660541/
https://www.ncbi.nlm.nih.gov/pubmed/33180785
http://dx.doi.org/10.1371/journal.pone.0241984
work_keys_str_mv AT tekelesabagebremichael extendedspectrumbetalactamaseandampcbetalactamasesproducinggramnegativebacilliisolatedfromclinicalspecimensatinternationalclinicallaboratoriesaddisababaethiopia
AT tekludejenieshiferaw extendedspectrumbetalactamaseandampcbetalactamasesproducinggramnegativebacilliisolatedfromclinicalspecimensatinternationalclinicallaboratoriesaddisababaethiopia
AT tullukassudesta extendedspectrumbetalactamaseandampcbetalactamasesproducinggramnegativebacilliisolatedfromclinicalspecimensatinternationalclinicallaboratoriesaddisababaethiopia
AT birrusamuelkinde extendedspectrumbetalactamaseandampcbetalactamasesproducinggramnegativebacilliisolatedfromclinicalspecimensatinternationalclinicallaboratoriesaddisababaethiopia
AT legesemelesehailu extendedspectrumbetalactamaseandampcbetalactamasesproducinggramnegativebacilliisolatedfromclinicalspecimensatinternationalclinicallaboratoriesaddisababaethiopia